pI: 6.5465 |
Length (AA): 703 |
MW (Da): 78549 |
Paralog Number:
0
Signal peptide: Y | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
79 | 536 | 5c0w (K) | 15 | 508 | 29.00 | 0 | 1 | 0.906696 | 0.55 |
179 | 540 | 4nlc (A) | 179 | 540 | 99.00 | 0 | 1 | 1.69011 | -1.26 |
462 | 536 | 2e1f (A) | 1149 | 1222 | 19.00 | 0 | 0.96 | 0.500726 | -1.56 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_127879)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G54440 | RRP6-like protein 1 |
Arabidopsis thaliana | AT5G35910 | exosome complex exonuclease RRP6L2 |
Babesia bovis | BBOV_IV002650 | exosome component 10, putative |
Brugia malayi | Bm1_09560 | 3'-5' exonuclease family protein |
Candida albicans | CaO19.7719 | likely 3'-5' exonuclease similar to S. cerevisiae RRP6 (YOR001W) nuclear exosome component involved in RNA processing |
Candida albicans | CaO19.58 | likely 3'-5' exonuclease similar to S. cerevisiae RRP6 (YOR001W) nuclear exosome component involved in RNA processing |
Caenorhabditis elegans | CELE_C14A4.4 | Protein CRN-3, isoform A |
Cryptosporidium hominis | Chro.50386 | hypothetical protein |
Dictyostelium discoideum | DDB_G0271572 | 3'-5' exonuclease |
Drosophila melanogaster | Dmel_CG7292 | CG7292 gene product from transcript CG7292-RC |
Escherichia coli | b1804 | ribonuclease D |
Echinococcus granulosus | EgrG_000568100 | Helicase RNase D C terminal HRDC domain |
Echinococcus granulosus | EgrG_002000900 | hypothetical protein |
Entamoeba histolytica | EHI_021400 | exosome component 10, putative |
Echinococcus multilocularis | EmuJ_000567700 | 3' 5' exonuclease |
Echinococcus multilocularis | EmuJ_000009300 | exosome component 10 |
Echinococcus multilocularis | EmuJ_000568100 | Helicase RNase D C terminal, HRDC domain |
Homo sapiens | ENSG00000171824 | exosome component 10 |
Leishmania braziliensis | LbrM.20.2660 | exosome subunit rrp6p homologue, putative |
Leishmania donovani | LdBPK_044330.1 | exosome subunit rrp6p homologue putative |
Leishmania infantum | LinJ.34.4330 | exosome subunit rrp6p homologue, putative |
Leishmania major | LmjF.34.3080 | exosome subunit rrp6p homologue, putative |
Leishmania mexicana | LmxM.33.3080 | exosome subunit rrp6p homologue, putative |
Loa Loa (eye worm) | LOAG_00677 | 3'-5' exonuclease |
Mycobacterium leprae | ML1040c | conserved hypothetical protein |
Mus musculus | ENSMUSG00000017264 | exosome component 10 |
Mycobacterium tuberculosis | Rv2681 | Conserved hypothetical alanine rich protein |
Mycobacterium ulcerans | MUL_3315 | hypothetical protein |
Neospora caninum | NCLIV_063640 | Ribonuclease D, related |
Oryza sativa | 4331677 | Os03g0157800 |
Oryza sativa | 9270208 | Os10g0437200 |
Saccharomyces cerevisiae | YOR001W | Rrp6p |
Schistosoma japonicum | Sjp_0206770 | Exosome component 10, putative |
Schistosoma mansoni | Smp_131150 | polymyositis/scleroderma autoantigen-related |
Schmidtea mediterranea | mk4.002369.05 | Polymyositis/scleroderma autoantigen-related |
Schmidtea mediterranea | mk4.002369.06 | Polymyositis/scleroderma autoantigen-related |
Trypanosoma brucei gambiense | Tbg972.4.1510 | ribosomal RNA processing protein 6, putative |
Trypanosoma brucei | Tb927.4.1630 | ribosomal RNA processing protein 6 |
Trypanosoma congolense | TcIL3000_4_1200 | ribosomal RNA processing protein 6, putative |
Trypanosoma cruzi | TcCLB.504057.110 | ribosomal RNA processing protein 6, putative |
Toxoplasma gondii | TGME49_246970 | 3'-5' exonuclease domain-containing protein |
Trichomonas vaginalis | TVAG_197890 | conserved hypothetical protein |
Trichomonas vaginalis | TVAG_283650 | hypothetical protein |
Trichomonas vaginalis | TVAG_053630 | conserved hypothetical protein |
Wolbachia endosymbiont of Brugia malayi | Wbm0258 | ribonuclease D |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
mtu2727 | Mycobacterium tuberculosis | non-essential | nmpdr |
Tb927.4.1630 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.4.1630 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.4.1630 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.4.1630 this record | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_C14A4.4 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_C14A4.4 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_C14A4.4 | Caenorhabditis elegans | slow growth | wormbase |
TGME49_246970 | Toxoplasma gondii | Probably essential | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in procyclic forms . | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
1 literature reference was collected for this gene.